Vesico uretric junction stone 4.6mm...management
Reading File
Finding Sources
Finding Sources
Searching PubMed
"ureteral stone" AND "medical expulsive therapy" AND "vesicoureteral junction"
Finding Sources
Searching PubMed
"ureteral calculi" AND "alpha blocker" AND "spontaneous passage"
Finding Sources
Finding Sources
Searching PubMed
"ureteral stone" AND "medical expulsive therapy"
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Let me compile the full management answer.
VUJ (Vesicoureteric Junction) Stone — 4.6 mm: Management
A 4.6 mm VUJ stone is a distal ureteric stone with a very favorable prognosis for spontaneous passage. Here is the complete management approach:
1. Initial Assessment
Imaging: Non-contrast CT KUB is the gold standard — sensitivity 98–99%, identifies stone size, density (Hounsfield units), and any proximal hydronephrosis. Plain KUB can follow radiopaque stones.
Indications for urgent/emergency intervention (bypass conservative management if any of these present):
- Fever/sepsis with obstructing stone → urgent decompression (ureteric stent or nephrostomy)
- Intractable pain despite adequate analgesia (>72 hours)
- Solitary kidney or bilateral obstruction
- Acute kidney injury / impaired renal function
- Complete obstruction
2. Conservative Management (First-line for 4.6 mm VUJ stone)
This is the appropriate first-line approach for an uncomplicated 4.6 mm distal stone.
Spontaneous passage rate:
- Stones < 4 mm: up to 80% pass spontaneously
- Stones 4–6 mm (including 4.6 mm): ~60–70% pass spontaneously
- Distal ureteric stones (including VUJ): up to 70% pass spontaneously — the highest passage rate of all ureteric locations
- Stones > 7 mm: passage rate drops sharply (~29% per MIMIC study data)
Observation period: 4–6 weeks of conservative management is appropriate.
Symptomatic treatment:
- NSAIDs (diclofenac, ketorolac) — first-line analgesia; reduce ureteric edema
- Opioids if NSAIDs insufficient
- Hydration (adequate oral intake; IV if needed)
3. Medical Expulsive Therapy (MET) — Key Intervention
MET is strongly recommended for distal ureteric stones ≤10 mm.
Mechanism: α₁-adrenoceptors (subtypes 1a and 1c) are concentrated in the smooth muscle of the distal one-third of the ureter and ureterovesical junction. Blockade causes ureteric dilation and reduces spasm, facilitating stone passage.
| Drug | Dose | Notes |
|---|---|---|
| Tamsulosin (α-blocker) | 0.4 mg once daily | Drug of choice — most evidence |
| Silodosin (α-blocker) | 8 mg once daily | Alternative, possibly superior |
| Nifedipine (CCB) | 30 mg once daily (modified release) | Alternative if α-blockers not tolerated |
Evidence: Meta-analyses show MET with α-blockers improves stone passage rate from 54% to 77% in distal ureteric stones ≤10 mm, with shortened time to expulsion (mean 7.7 days vs 18 days with analgesia alone) and fewer colic episodes. A 2025 network meta-analysis (Taheri et al., BMC Urol, PMID 39875883) specifically compared combinations for distal ureteric stones.
⚠️ Note: One large UK RCT (SUSPEND trial) found no significant benefit from MET, and the MIMIC study offered mixed data. However, most international guidelines (EAU, AUA) still recommend MET for distal stones ≤10 mm, and the balance of meta-analytic evidence supports its use.
Duration: Continue MET for up to 4 weeks or until stone passage is confirmed.
4. Follow-up
- Repeat imaging at 4–6 weeks (ultrasound or low-dose CT KUB) to confirm passage
- Strain urine to retrieve stone for composition analysis
- Assess for hydronephrosis on follow-up
5. Surgical Intervention (if conservative/MET fails after 4–6 weeks, or patient desires early intervention)
For a 4.6 mm VUJ stone, if not passed:
| Modality | Role for VUJ/Distal Ureter Stone |
|---|---|
| Ureteroscopy (URS) + Holmium laser lithotripsy | Procedure of choice — stone-free rate ~96–100% for distal ureteric stones; semi-rigid ureteroscope used |
| ESWL (Shock Wave Lithotripsy) | Option for proximal/mid-ureteric stones; lower success for VUJ; stone must be fragmented then passed |
| PCNL | Not indicated for this stone size/location |
| Open surgery | Obsolete (<1% of cases) |
URS is the definitive surgical treatment: a semi-rigid ureteroscope is advanced to the VUJ under direct vision; the stone is fragmented with a holmium:YAG laser or removed with a nitinol basket. Stone-free rates at the distal ureter reach 96–100% (Campbell-Walsh-Wein Urology). A ureteric stent may be placed post-procedure, which is a temporary source of morbidity.
6. Metabolic Work-up (Secondary Prevention)
For first-time stone formers: basic metabolic panel, serum calcium, uric acid, urinalysis, and urine culture. A full 24-hour urine metabolic evaluation is indicated for recurrent stone formers.
Summary Algorithm
4.6 mm VUJ stone, no sepsis, pain controlled
↓
Conservative management + MET (Tamsulosin 0.4 mg OD)
↓
Review at 4–6 weeks with imaging
↓
Stone passed? → Metabolic work-up, prevention counselling
Stone NOT passed? → URS + laser lithotripsy (procedure of choice)
↓
Any time: fever / AKI / intractable pain → urgent ureteric stent or nephrostomy
Sources: Comprehensive Clinical Nephrology 7th Ed; Schwartz's Principles of Surgery 11th Ed; Campbell-Walsh-Wein Urology; PMID 39875883 (2025 network meta-analysis, distal ureteral stone MET combinations)
This is a shared conversation. Sign in to Orris to start your own chat.